OCT BIOMARKER AND THEIR APPLICATION IN EVALUATING ANTIVEGF RESPONSE IN TYPE 2 DIABETIC MACULOPATHY

Introduction: Diabetic maculopathy is a result of diabetic retinopathy and it involves impairment of the macula, which is the “center region of the retina that responsible for central vision”. Aim and Objective: To access the OCT biomarker and their application in evaluating anti VEGF response in Type 2 Diabetic maculopathy. Material and Method: Prospective observational study, carried out on 100 patients in department of ophthalmology in BRD medical collage in a duration of 12 months ( may 2023-april 2024). Results: p-value of CMT, SRF and HRF are less then 0.001 (signicant) whereas it is more then 0.05 in DRIL, IRCS and EZD (not signicant). Conclusion: OCT markers in evaluating “the response to anti-VEGF therapy in Type 2 Diabetic Maculopathy”. The identied OCT biomarkers, such as Central Macular Thickness (CMT), Subretinal Fluid (SRF) and Hyperreective Foci (HRF) effectively predicted anatomical changes in patients treated with intravitreal ranibizumab. The research found a signicant association between OCT morphological changes and functional improvement (visual acuity), conrming that OCT markers are valuable in assessing treatment outcomes.